A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

PHASE3CompletedINTERVENTIONAL

Enrollment

594

Participants

Timeline

Start Date

July 16, 2019

Primary Completion Date

July 14, 2021

Study Completion Date

July 14, 2021

Conditions

Gout

Interventions

DRUG

SHR4640 dose1

tablets，dose1，QD

DRUG

SHR4640 dose2

tablets，dose2，QD

DRUG

Placebo oral tablet

tablets，QD

DRUG

Allopurinol 300 MG

tablets，300mg，QD

Trial Locations (1)

RenJi Hospital Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04052932 - A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout | Biotech Hunter | Biotech Hunter